Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials

Urology

Volumn 57, Issue 4 SUPPL. 1, 2001, Pages 174-177

  Moul, Judd W ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b Center for Prostate Disease Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CAUCASIAN; CLINICAL TRIAL; ETHNOLOGY; FORECASTING; HUMAN; MALE; MIDDLE AGED; NEGRO; PROSTATE HYPERTROPHY; PROSTATE TUMOR; REFERENCE VALUE; RISK; SOLDIER; UNITED STATES;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; AGED; CASE-CONTROL STUDIES; CLINICAL TRIALS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FORECASTING; HUMANS; MALE; MIDDLE AGED; MILITARY PERSONNEL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REFERENCE VALUES; RISK; UNITED STATES;

EID: 0035320885     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0090-4295(00)00967-5     Document Type: Article

References (13)

1. Polascik TJ, Oesterling JE, and Partin AW: Prostate specific antigen: a decade of discovery - What we have learned and where we are going. J Urol 162: 293-306, 1999.
2. Friedrich MJ: Issues in prostate cancer screening. JAMA 281: 1573-1575, 1999.
3. Stephenson RA: Population-based prostate cancer trends in the PSA era: data Irom the Surveillance, Epidemiology, and End Results (SEER) program. Mongr Urol 19: 1-19, 1998.
4. Benson MC, Whang IS, and Pantuck A: Prostate specific antigen density: a means for distinguishing BP and prostate cancer. J Urol 147: 815-816, 1992.
5. Carter HB, Pearson ID, Metter EJ, et al: Longitudinal evaluation ol prostate-specific antigen levels in men with and without prostate disease. JAMA 278: 1251-1255, 1997.
6. Oesterling JE, Jacobsen SJ, Chute CG, et al: Serum prostate-specific antigen in a community-based population of healthy men: establishment of age reference ranges. JAMA 270: 860-864, 1993.
7. Morgan TO, Jacobsen SJ, McCarthy WE, et al: Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 335: 304-310, 1996.
8. Catalona WJ, Partin AW, Slawin KM, et al: Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279: 1542-1547, 1998.
9. Kelloff GJ, Lieberman R, Brawer MK, et al: Strategies for chemoprevention of prostate cancer. Prostate Cancer Prostatic Dis 1(suppl): 1-7, 1998.
10. Gann PH, Hennekens CH, and Stamfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 273: 289-294, 1995.
11. Anon.: Commentary: Profile: The Department of Defense, Center for Prostate Disease Research. Oncology 13: 1336-1340, 1999.
12. Preston DM, Levin LI, Jacobson DJ, et al: Prostate-specific antigen levels in young white and black men 20 to 45 years old. Urology 56: 812-816, 2000.
13. Hartzell JD, Kao T, Holland JC, et al: Age-specific reference ranges in prostate-specific antigen in young men: retrospective study from the National Defense University. Prostate J (in press).